Off-Label Use Of Incobotulinumtoxin A (Xeomin) For Treatment Of Patients With Idiopathic Overactive Bladder
Collection: PFD Week 2017
Credits: None available.
Type: Session
Speakers:
  • Hemikaa Devakumar, Section of Urogynecology & Reconstructive Pelvic Surgery, Cleveland Clinic Florida
A Cost-Effectiveness Analysis Of Botox Botulinum-A Toxin As First-Line Treatment For Overactive Bladder
Collection: PFD Week 2017
Credits: None available.
Type: Session
Speakers:
  • Charelle M. Carter-Brooks, MD, MSc, Magee-Womens Hospital of UPMC, Department of Obstetrics, Gynecology and Reproductive Sciences of the University of Pittsburgh, Division of Urogynecology and Reconstructive Surgery; Magee-Womens Hospital of UPMC; UPMC
Does A Recent Urinary Tract Infection (Uti) Increase The Risk Of Post-Injection Uti After Onabotulinum Toxin A?
Collection: PFD Week 2017
Credits: None available.
Type: Session
Speakers:
Collection: PFD Week 2017
Credits: None available.
Type: Session
Speakers:
Recurrence of Overactive Bladder Symptoms in Patients with Bmi > 30 Kg/M2 Vs. Bmi < 30 Kg/M2 After Intradetrusor Botox Injection
Collection: PFD Week 2016
Credits: None available.
Type: Session
Speakers:
  • Andrey Petrikovets, MD, Department of Obstetrics and Gynecology, Case Western Reserve University School of Medicine
What Is the True Rate of Urinary Retention Requiring Catheterization After Botox Injection
Collection: PFD Week 2016
Credits: None available.
Type: Session
Speakers:
Resting Maximum Urethral Closure Pressures Measured by High-Resolution Manometry Increase After Urethral Bulking Injection
Collection: PFD Week 2016
Credits: None available.
Type: Session
Speakers:
  • Erika Wasenda, MD, Division of Female Pelvic Medicine & Reconstructive Surgery, University of California, San Diego
Trigger Point Injections: Tips and Tricks
Collection: PFD Week 2016
Credits: None available.
Type: Session
Speakers: